DHG PHARMACEUTICAL JOINT-STOCK COMPANY (CÔNG TY CỔ PHẦN DƯỢC HẬU GIANG) continues to lead Vietnam’s pharmaceutical industry as a benchmark for scale, profitability, and sustainable growth. Founded in 1974 and headquartered in Can Tho City, DHG has evolved into the largest and most consistently profitable domestic pharmaceutical company in Vietnam. It operates under business ID and tax code 1800156801 and is publicly listed on the Ho Chi Minh Stock Exchange (HOSE) under the ticker symbol DHG.

DHG PHARMACEUTICAL is legally structured as a public joint stock company, with a solid base of institutional and public shareholders. Among them, Taisho Pharmaceutical Co., Ltd. from Japan is the largest foreign strategic investor, holding a controlling stake. The company's executive leadership includes seasoned professionals in both Vietnamese and international pharmaceutical operations. Mr. Doan Duy Khuong currently serves as Chairman, with Ms. Pham Thi Viet Nga, the former long-time CEO, remaining an influential figure in strategic direction.

In 2023, DHG PHARMACEUTICAL posted total revenue of USD 200.68 million and an outstanding net profit of USD 32.00 million, achieving the highest profit margin among major Vietnamese pharmaceutical firms. The company reported total assets of USD 193.22 million and owner’s equity of USD 173.57 million, highlighting its conservative financial posture and excellent capital management. These indicators reflect DHG’s robust operational efficiency, high return on equity, and low dependence on external debt.

The company’s success is underpinned by its expansive GMP-WHO certified manufacturing facilities, a diversified product portfolio of over 300 items, and an integrated nationwide distribution network. DHG produces a wide range of medicines, including antibiotics, vitamins, OTC products, and traditional herbal remedies. It has also embraced international standards, entering partnerships to produce drugs under Japanese GMP protocols, giving it a strong competitive edge in both domestic and export markets.

With continued investment in R&D, digital transformation, and supply chain modernization, DHG PHARMACEUTICAL is not only a market leader in Vietnam but also an emerging player in regional pharmaceutical markets. It remains a model of corporate governance, product innovation, and financial discipline.

For institutional investors, healthcare buyers, and regulatory bodies, Vanguard Business Information LLC (VBI)provides in-depth company reports, risk assessments, and shareholder verification on DHG PHARMACEUTICAL and other leading firms. As of 2024, DHG’s strong performance places it at the forefront of Vietnam’s pharmaceutical future.